Counterfeit Botulinum Toxin and Cosmetic Iatrogenic Botulism: Emerging Threats that Require Regulatory Reform
Main Article Content
Keywords
botulism, botulinum toxin, cosmetic, counterfeit, unlicensed personnel, healthcare reform
Abstract
Background: There has been a concerning increase in reported cases of cosmetic iatrogenic botulism (CIB) linked to botulinum neurotoxin type A (BoNTA) injections performed by unlicensed or untrained individuals or involving counterfeit BoNTA products administered in non-healthcare settings.
Methods: A search was conducted across PubMed, Google Scholar, and Cochrane databases from their inception to identify reports in English regarding CIB linked to procedures carried out by unlicensed or untrained individuals or involving counterfeit BoNTA products. Reviews, letters, and commentaries were excluded. Additionally, online searches were performed to locate reports from Federal and State Boards and Medical Societies.
Results: Ten reports of such occurrences were identified, six in the United States and four globally, involving a total of 303 participants. Four of these reports included health advisories issued by the Centers for Disease Control and Prevention (CDC) and State Boards. All but two reports specified the patient’s gender, with a predominance of female patients. Symptoms of botulism typically began within three days of procedure–the most common initial symptoms were blurred vision and ptosis. Approximately half of the patients required hospitalization. When administered, botulism antitoxin proved immediately effective, leading to shorter hospital stays and no fatalities.
Discussion: The regulatory gaps that may contribute to unsafe practices in this area are highlighted. There is an urgent need for unified national regulations in the United States, along with global standards, to clearly define who is authorized to perform these procedures and under what conditions they can do so. Furthermore, it is essential to enhance enforcement measures and increase public awareness to protect patients and uphold the highest safety standards.
References
2. Mohapatra RK, Mishra S, Tuglo LS. Surge in iatrogenic botulism cases in Europe: Threat perceptions and salient countering measures. New Microbes New Infect. 2023;53:101142. doi: 10.1016/j.nmni.2023.101142
3. Chertow DS, Tan ET, Maslanka SE, et al. Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA. 2006;296(20):2476-2479. doi:10.1001/jama.296.20.2476
4. CDC. Adverse events associated with counterfeit or mishandled botulinum toxin injections. [Online]; 2024. Available at: https://emergency.cdc.gov/han/2024/han00507.asp
5. Thomas CM, McElroy R, Yackley J, et al. Notes from the field: illnesses after administration of presumed counterfeit botulinum toxin in nonmedical settings - Tennessee and New York City, March 2024. MMWR Morb Mortal Wkly Rep. 2024;73(27):609-611. doi: 10.15585/mmwr.mm7327a3
6. Illinois Department of Public Health. IDPH alerts healthcare providers to cluster of illnesses associated with botulinum toxin injections. [Online]; 2024. Available at: https://dph.illinois.gov/resource-center/news/2024/april/2024-04-08---idph-alerts-healthcare-providers-to-cluster-of-illn.html. Accessed July 16, 2025.
7. Dawson EF, Pateriya S, Blashinsky ZA, Landa-Galindez A. From Botox party to botulism: a case report and public health warning on adulterated botulinum toxin injection. Cureus. 2024;16(8):e68016. doi: 10.7759/cureus.68016
8. Massachusetts Department of Public Health (DPH). DPH alerts public to Botox-related botulism cases linked to Rodrigo Beauty in Milton. [Online]; 2025. Available at: https://www.mass.gov/news/dph-alerts-public-to-botox-related-botulism-cases-linked-to-rodrigo-beauty-in-milton
9. Chen Z, Chen ZY, Liu WH, Li GS. Botulism due to cosmetic injection of botulinum toxin: five-year experience. Plast Reconstr Surg. 2021;148(2):335e-337e. doi: 10.1097/PRS.0000000000008173
10. Qiu H, Shen J, Tang Y, Ji Q, Lin X, Wu D. A retrospective case series study of illegal cosmetic iatrogenic botulism: outbreak analysis and response lessons. Aesthet Surg J. Published online May 20, 2025. doi:10.1093/asj/sjaf088
11. Euractiv. Bulgarian Botox injuries surge, authorities launch investigation. [Online]; 2025. Available at: https://www.euractiv.com/section/health-consumers/news/bulgarian-botox-injuries-surge-authorities-launch-investigation/
12. BBC News. UK cases of botulism linked to cosmetic injections investigated [Online]; 2025. Available at: https://www.bbc.com/news/articles/c628e5ez78yo
13. CDC. Botulism (Clostridium botulinum). 2011 Case Definition. [Online]; 2021. Available at: https://ndc.services.cdc.gov/case-definitions/botulism-2011/
14. de Oliveira GV, Rodrigues Cordeiro AA, Portela LC, Hexsel D, Palermo E, Ravelli FN, et al. Impact of unlawful aesthetic practices in Brazil: a multicenter survey on complications and the need for regulatory reform. Dermatol Surg. 2025 July 15. doi: 10.1097/DSS.0000000000004774. Online ahead of print.
15. Myers A. Who Can Legally Perform Botox and Fillers: A State-by-State Guide. [Online]; 2024. Available at: https://www.nextech.com/blog/who-can-perform-botox-and-derm-fillers
16. Byrd MS. Who can legally perform Botox? Banter [Online]; 2023. Available at: https://byrdadatto.com/banter/who-can-legally-perform-botox/
17. Weitz Morgan PLLC. Prescription drugs in med spas: legal considerations for botox and fillers. [Online]; 2023. Available at: https://www.weitzmorgan.com/post/prescription-drugs-in-med-spas-legal-considerations-for-botox-and-fillers
18. Hold D. Avoiding liability: legal and ethical considerations when offering Botox. [Online]; 2024. Available at: https://djholtlaw.com/avoiding-liability-legal-and-ethical-considerations-when-offering-botox/#:~:text=This%20exam%20establishes%20the%20physician,occurs%20within%20the%20allowed%20parameters
19. Donnell CC, Woolley JJ, Worthington SW. Advertising and facial aesthetics in primary care: how compliant are practice websites and social media with published guidance? Br Dent J. 2021 Mar 25:1–9. doi: 10.1038/s41415-021-2718-4
20. Song SY, Lee JH, Kim SC, Choi JW, Bae J, Kim E. Complaints addressed by regulatory authorities in drug advertising targeted at consumers: Cases across three, different countries. Res Social Adm Pharm. 2019;15(10):1274-1279. doi:10.1016/j.sapharm.2018.12.001
21. Fox A, Crawford-Williams F, Ria J, et al. Is the Australian nursing workforce ready to embrace prescribing under supervision? A cross-sectional survey. J Adv Nurs. 2022;78(12):4082-4091. doi: 10.1111/jan.15367.
22. Park J, Han X, Pittman P. Does expanded state scope of practice for nurse practitioners and physician assistants increase primary care utilization in community health centers? J Am Assoc Nurse Pract. 2020;32(6):447-458. doi: 10.1097/JXX.0000000000000263.
23. Sadik K, Flener J, Gargiulo J, et al. A US hospital budget impact analysis of a skin closure system compared with standard of care in hip and knee arthroplasty. Clinicoecon Outcomes Res. 2018;11:1-11. doi: 10.2147/CEOR.S181630
24. Rossi AM, Wilson B, Hibler BP, Drake LA. Nonphysician practice of cosmetic dermatology: a patient and physician perspective of outcomes and adverse events. Dermatol Surg. 2019;45(4):588-597. doi: 10.1097/DSS.0000000000001829.
25. Beer K, Rothschild K. Importing injectables. J Drugs Dermatol. 2014;13(9):1156-1158. PMID: 25226018
26. Bradshaw S. Cosmetic practitioners take huge risks purchasing and administering illegal botulinum toxin drug products. J Drugs Dermatol. 2017;16(9):936-938. PMID: 28915291
27. FDA. Counterfeit version of Botox found in multiple states. [Online]; 2025. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/counterfeit-version-botox-found-multiple-states#:~:text=Purchasing%20and%20administering%20counterfeit%20products,Protecting%20Patients%20from%20Unsafe%20Drugs
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.
Gisele Viana de Oliveira, Faculty of Medical Sciences of Minas Gerais, FCMMG, Belo Horizonte, MG, Brazil
Prof. of Dermatology
Disha Chakraborty, Mayo Clinic, Rochester, MN, USA
Department of Dermatology
George Kroumpouzos, Department of Dermatology, Warren Alpert Medical School at Brown University
Clinical Associate Professor of Dermatology